Serum levels of leptin are decreased in underweight AN patients and increase with weight restoration. To assess the relationship of decreased leptin levels with other hormonal abnormalities in AN and to evaluate the possible role of increasing leptin levels, alone or in combination with other hormones, in the resumption of menses that accompanies weight gain, we studied crosssectionally sixty-five consecutively enrolled AN patients. Subjects were divided in three groups: (I) underweight and amenorrheic; (II) weight-recovered but still amenorrheic; and (III) weight-recovered and eumenorrheic women. Patients in group I had decreased BMI, serum leptin, estradiol (E2), insulin-like growth factor 1 (IGF-1) and urinary growth hormone (GH) levels and increased sex hormone-binding globulin (SHBG) levels, compared to AN patients in groups II and III. Moreover, although no differences in leptin levels or BMI were observed between amenorrheic and eumenorrheic weight-recovered patients (groups II and III), free E2 and GH levels were higher (PϽ0.02) in weight-recovered, eumenorrheic women. Thus, it appears that leptin is a necessary, but not a sufficient, factor for the resumption of menses in AN patients.
Anorexia nervosa (AN) is a disorder characterized by abnormally low body weight, amenorrhea and specific psychopathologic features including intense fear of gaining weight and an abnormal way one's body weight, size or shape is perceived. [1] [2] [3] In addition, patients with AN have several endocrine abnormalities. These include abnormalities of the growth hormone (GH)-insulin-like growth factor 1 (IGF-1) axis 4, 5 as well as decreased serum estrogen levels due to dysfunction of the hypothalamic-pituitary-gonadal axis 6, 7 that leads to amenorrhea, anovulation, vaginal and breast atrophy. 2, 3 Based on the notion that initiation and maintenance of menstrual cycles would require the presence of a minimum amount of body fat to ensure adequate energy stores needed to sustain pregnancy and provide nutrition to the fetus, it has been previously proposed that the abnormal hypothalamicpituitary-gonadal function in anorexia nervosa could be the result of excessive weight loss. 8, 9 Until recently this hypothesis remained unproven however, since the potential molecular link between decreased adipose stores and the hypothalamic-pituitary-gonadal axis had not been identified.
Our understanding of the interaction between adipose stores and the reproductive system was recently greatly advanced by the discovery of leptin, 10 an adipocyte secreted hormone, whose circulating levels are directly associated with the amount of energy stored as fat. Leptin is the signal by which information about the amount of energy stores is conveyed to the brain, and thus, influences food intake and energy expenditure.
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In addition, a much broader spectrum of activities for this hormone has been recently suggested. 11, 12 More specifically, it has been proposed that leptin regulates several neuroendocrine axes, including the hypothalamic-pituitary-gonadal axis. [11] [12] [13] Moreover, recent experimental evidence suggests that leptin could also influence GH secretion 14 and cross-sectional data demonstrate that leptin is associated with GH and/or IGF-1 levels in normal and GH-deficient subjects. 4, 15, 16 Thus, since AN is characterized by abnormalities of the hypothalamic-pituitary-gonadal and the GH-IGF-1 axes that directly influence normal reproductive capacity, 20 and since AN is also characterized by low serum and CSF leptin levels that can be normalized in response to normalization of their BMI, [17] [18] [19] it has been proposed that leptin mediates normalization of reproductive function. However, it remains unknown whether restoration of normal leptin levels is the only necessary factor, or whether it is simply a permissive factor for normalization of menstrual function.
We measured circulating leptin, SHBG and estradiol levels, and assessed the GH-IGF-I axis in 65 consecutively enrolled AN patients. Leptin levels were positively correlated with BMI (r = 0.47, P Ͻ 0.0001) and E2 (r = 0.43, P Ͻ 0.005) in the entire study group while correlations between leptin levels and IGF-1 (r = 0.16), IGF BP-1 (r = 0.16) and IGF BP-3 (r = 0.12) did not achieve statistical significance at the conventional P = 0.05 level. Underweight AN patients in the active phase of their disease (group I) have markedly decreased BMI accompanied by decreased levels of serum leptin, E2, IGF-I, and urinary GH as well as increased serum levels of SHBG when compared to weight-recovered AN patients (stages II and III, Table  1 ). Furthermore, this cross-sectional study revealed no differences in either BMI or leptin levels between eumenorrheic and amenorrheic weight-recovered women (stages II and III). However, despite similar BMI and serum leptin levels, weight-recovered AN subjects with normal menstrual periods, had increased serum free E2 and urinary GH (P Ͻ 0.05) in comparison to weight-recovered but amenorrheic subjects (Table 1) . When analysis of covariance was used to evaluate the differences among the three study groups after adjusting for BMI, leptin levels of the underweight AN patients remained significantly different from leptin levels in amenorrheic or eumenorrheic weight-recovered women (t = 3.5, P = 0.0009, and t = 2.7, P = 0.008, respectively) and urinary GH and free E2 levels remained significantly different between groups II and III (t = 3.1, P = 0.0005 and t = 2.1, P = 0.04 respectively). Our data confirm previous findings that AN patients have low serum leptin, IGF-1 and E2 which increase in response to refeeding and normalization of BMI. Furthermore, our data confirm previous observations 5, 21 of a different effect of low weight on IGFBP-1 and IGFBP-3. Levels of IGFBP-1 are increased, whereas IGF-1 and IGFBP-3, the major IGF-1 binding protein regulated by GH and nutrition, appear to be decreased in the low weight AN patients and moderately increased after weight gain. 7, [21] [22] [23] In addition, although it has been previously reported that low weight AN patients, particularly those who have been markedly undernourished for a long period of time, have abnormal serum GH, 5 a study published while the present study was in review reported that serum GH is not significantly different in AN than in controls and does not change significantly in response to weight gain. 23 Urinary GH levels, a test that may provide better information about integrated, 24-h GH secretion, has not been previously studied in women with AN. In this study, we demonstrate for the first time that urinary GH levels are lower in underweight AN patients, whereas weight restoration and the accompanying increase in leptin levels is associated with an increase in urinary GH levels. This could be either due to increasing leptin levels per se, since leptin has previously been shown to increase GH secretion in animal studies, 14 or to the increasing E2 levels, as previously shown in postmenopausal women treated with estrogen. 24 Finally, this study suggests that eumenorrheic and amenorrheic women with AN have similar leptin levels after weight restoration, which are in both cases above the previously determined threshold for normalization of reproductive function (1.85 ng ml −1 ). This is consistent with the notion that leptin plays a permissive role in the restoration of menses and that other hormonal factors should also be fully normalized before regular menstrual periods are restored. 19 Thus, we measured several other hormones to explore further whether serum estrogen levels or activation of the GH-IGF-1 axis in response to weight restoration differ in eumenorrheic and amenorrheic women with AN. In our study eumenorrheic women had significantly higher serum-free E2 and urinary GH levels than amenorrheic patients with similar BMI and leptin levels.
Since severe dietary restriction and/or strenuous physical activity are typical causes of secondary amenorrhea, 25, 26 it has been suggested that the hypothalamic-pituitary-gonadal dysfunction associated with AN is a direct result of starvation and weight loss 27 and that the onset and maintenance of menstrual cycles would require the presence of a minimum amount of body fat. 8, 9 Leptin, an adipocyte-secreted protein, 10 that regulates energy homeostasis and neuroendocrine function 11, 12 was recently proposed to be the hormone responsible for the weight loss-induced reproductive dysfunction in animal and human studies. 11, 12, 19, 28 More specifically, it has been previously shown that exogenous leptin administration activates the hypo-thalamic-pituitary-gonadal and thyroid axes while depressing the hypothalamic-pituitary-adrenal axis in starving rodents. 13 Moreover, experimental evidence suggests that exogenous leptin administration rescues the reproductive failure in genetically obese, leptindeficient ob/ob mice 29, 30 and accelerates the onset of puberty in mice. 31 Furthermore, observational studies have recently suggested that increasing leptin levels may signal the onset of puberty in humans. 32 Finally, it has recently been demonstrated that the pulsatile secretion of leptin is synchronous to the secretion of LH and estradiol in normal women, 33 suggesting that low leptin levels may play an important role in the dysfunction of the hypothalamic-pituitary-ovarian axis observed in AN and cachexia. 34 Women with AN typically present with an immature prepubertal pattern of LH secretion that results in anovulatory cycles, 26 and normal LH secretion in AN patients is restored with refeeding when a certain level of weight gain is achieved. 26 Based on these observations, it would be reasonable to expect that decreased leptin levels in underweight patients with AN could be responsible for the amenorrhea these patients have and that increasing leptin concentrations that accompany refeeding would restore regular menses. Indeed, recent observational data provide support to this hypothesis and demonstrate that all weight-recovered AN women with normal menstrual periods have circulating leptin levels above a certain threshold. 19 However, since leptin levels in AN patients rise considerably above this critical threshold point during weight gain without leading to rapid onset of menstruation, it has been recently hypothesized that the physiological normalization of menstrual periods not only takes time but may also depend on additional factors. 19 This study confirms this hypothesis by indicating that elevated serum-free estradiol levels and, possibly activation of the GH-IGF-1 axis, may also be needed for normalization of menstrual periods in these women. In addition, the fact that leptin correlates significantly with E2 levels indicates that leptin may affect circulating levels of E2 as previously suggested. 33 Thus, since the differences in hormone levels among the three study groups are independent of obesity and since free E2 and GH levels differ between amenorrheic and eumenorrheic women despite their similar body weight and leptin levels, it can be reasonably argued that leptin increasing above a threshold level may be a necessary but not sufficient factor for the restoration of menses in AN patients. However, the cross-sectional nature of this study cannot clarify whether the changes of free E2 levels and GH-IGF-1 axis that are observed in eumenorrheic AN patients are the direct result of increasing leptin levels requiring a latent period to act after leptin exceeds a critical threshold level, or whether they are produced by other, not yet identified, hormonal or metabolic factors. Similarly, whether the changes of the GH-IGF-1 axis are produced directly by the increasing leptin levels or whether they are secondary to changes in serum E2 or other factors remains to be elucidated. Since these questions cannot be resolved by a cross-sectional study, future interventional studies will be needed to fully clarify the time sequence and pathophysiological mechanisms underlying the above clinical and hormonal changes.
Material and methods
Sixty-five consecutively enrolled female outpatients diagnosed with AN according to DSM-IV criteria consented to participate in this study. All women had a history of normal menarche and at least 3 months of regular menses prior to presenting with secondary amenorrhea due to AN. No subject of this study was taking exogenous hormone preparations. The protocol was designed and carried out in accordance with the Hospital Materno Infantil Vall' Hebron ethics committee guidelines, approval was granted and informed consent was obtained from each patient. Subsequent to enrollment, participants were divided into three groups according to their clinical status: (I) active phase: undernourished and underweight amenorrheic women (defined as BMI lower than −1 Standard Deviation (SDS) for the subject's age and amenorrhea for more than 3 months) (n = 27); (II) weight-recovered but still amenorrheic women (BMI higher than −1 SDS but amenorrheic for more than 3 months after weight recovery) (n = 21); and (III) fully recovered women (BMI higher than −1 SDS with regular menses for more than 3 months after weight recovery) (n = 17).
Anthropometric (body weight, height) and gynaecologic data (age at menarche, duration of amenorrhea and duration of normal menstruation after weight recovery) were obtained and recorded by a board certified gynecologist. BMI was calculated as weight/(height × height) and compared to the respective age-specific values. Baseline blood samples were obtained between 8 and 9 am after an overnight fast and a 24-h urine sample was collected preceding the blood draw. Blood was drawn during the follicular phase of menstrual cycle (days 2-5) for patients with regular menstruation. Serum samples were analyzed blindly for leptin, IGF-I, IGFBP-3, IGFBP-1, E2 and SHBG concentrations. GH concentrations were measured in the urine samples. Leptin was measured as previously described. 35, 36 IGF-I was measured by RIA (Mediagnost-Biomérieux, Marcy l'Etoile, France) after separation of potentially interfering IGFBPs using excess IGF-II in acidified samples. IGFBP-3 was measured by RIA (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA), IGFBP-1 by ELISA (Medix Biochemica Ab, Kaunianien, Finland), E2 by RIA (Orion Diagnostica, Espoo, Finland), SHBG by IRMA (Diagnostic Products Corporation, Los Angeles, CA, USA) and urinary GH by IRMA (Biomérieux, Marcy l'Etoile, France). Differences of anthropometric and hormonal data among the three groups were analyzed by ANOVA with post-hoc tests. Analysis of covariance was used to control for the potential confounding effect of BMI on differences observed among study groups. Leptin levels were not normally distributed and, thus, log-transformed leptin data were used for simple and multiple linear regression analyses. Results were considered significant at the conventional PϽ0.05 level. Statistical analysis was performed using Statview 4.5 version for Macintosh.
